JP2021522269A5 - - Google Patents
Info
- Publication number
- JP2021522269A5 JP2021522269A5 JP2020560257A JP2020560257A JP2021522269A5 JP 2021522269 A5 JP2021522269 A5 JP 2021522269A5 JP 2020560257 A JP2020560257 A JP 2020560257A JP 2020560257 A JP2020560257 A JP 2020560257A JP 2021522269 A5 JP2021522269 A5 JP 2021522269A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- integrin
- group
- cargo molecule
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024232254A JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US62/663,763 | 2018-04-27 | ||
| US201962790372P | 2019-01-09 | 2019-01-09 | |
| US62/790,372 | 2019-01-09 | ||
| PCT/US2019/029393 WO2019210200A1 (en) | 2018-04-27 | 2019-04-26 | Integrin targeting ligands and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024232254A Division JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522269A JP2021522269A (ja) | 2021-08-30 |
| JP2021522269A5 true JP2021522269A5 (enExample) | 2022-06-14 |
| JP7704529B2 JP7704529B2 (ja) | 2025-07-08 |
Family
ID=68294255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
| JP2024232254A Pending JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024232254A Pending JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12667619B2 (enExample) |
| EP (2) | EP4435000A3 (enExample) |
| JP (2) | JP7704529B2 (enExample) |
| KR (1) | KR102787533B1 (enExample) |
| CN (2) | CN112074290B (enExample) |
| AU (1) | AU2019260738B2 (enExample) |
| BR (1) | BR112020021949A2 (enExample) |
| CA (1) | CA3097656A1 (enExample) |
| DK (1) | DK3784269T3 (enExample) |
| ES (1) | ES2983950T3 (enExample) |
| FI (1) | FI3784269T3 (enExample) |
| HR (1) | HRP20240907T1 (enExample) |
| IL (2) | IL309955A (enExample) |
| JO (1) | JOP20200266A1 (enExample) |
| MX (1) | MX2020011290A (enExample) |
| SA (1) | SA520420426B1 (enExample) |
| SG (1) | SG11202009734VA (enExample) |
| SI (1) | SI3784269T1 (enExample) |
| TW (1) | TW202014206A (enExample) |
| WO (1) | WO2019210200A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309955A (en) | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
| KR20210113273A (ko) | 2019-01-09 | 2021-09-15 | 애로우헤드 파마슈티컬스 인코포레이티드 | HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
| AU2021342155A1 (en) * | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| EP4367246A4 (en) * | 2021-07-07 | 2026-07-29 | Alnylam Pharmaceuticals Inc | Integrin-targeting ligands for the ocular administration of arni compounds |
| CN121399119A (zh) * | 2023-06-19 | 2026-01-23 | 广东众生睿创生物科技有限公司 | 一种整合素配体及其用途 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| WO2025261536A1 (zh) * | 2024-06-21 | 2025-12-26 | 长春金赛药业有限责任公司 | 一种整联蛋白配体关键中间体及其制备方法 |
| WO2026034639A1 (ja) * | 2024-08-09 | 2026-02-12 | 株式会社Spin Wave | ペプチド合成用可溶性担体およびこれを用いた合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| SK9192000A3 (en) * | 1997-12-17 | 2001-03-12 | Merck & Co Inc | Integrin receptor antagonists |
| AU2002337954C1 (en) | 2001-10-22 | 2008-10-23 | The Scripps Research Institute | Integrin targeting compounds |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| EP3673922A1 (en) * | 2008-03-14 | 2020-07-01 | VisEn Medical, Inc. | Integrin targeting agents and methods of using same |
| JP2012517447A (ja) | 2009-02-10 | 2012-08-02 | ザ スクリプス リサーチ インスティチュート | 化学的にプログラムされたワクチン接種法 |
| US9586916B2 (en) * | 2012-01-27 | 2017-03-07 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 |
| JP6383735B2 (ja) | 2013-01-28 | 2018-08-29 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Ｒｓウイルスの抗ウイルス剤としてのキノキサリノンおよびジヒドロキノキサリノン |
| HK1214301A1 (zh) * | 2013-02-28 | 2016-07-22 | 箭头研究公司 | 治療epas1相關疾病的有機組合物 |
| WO2015021092A1 (en) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| EP3273965A4 (en) | 2015-03-26 | 2018-12-05 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
| US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| JP2018514568A (ja) * | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
| TWI761305B (zh) | 2015-05-29 | 2022-04-21 | 美商愛羅海德製藥公司 | 抑制Ｈｉｆ２α基因表現之組合物及方法 |
| CN120247964A (zh) | 2018-02-17 | 2025-07-04 | 箭头药业股份有限公司 | 三炔连接剂和使用方法 |
| IL309955A (en) * | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
-
2019
- 2019-04-26 IL IL309955A patent/IL309955A/en unknown
- 2019-04-26 DK DK19794009.1T patent/DK3784269T3/da active
- 2019-04-26 US US17/050,042 patent/US12667619B2/en active Active
- 2019-04-26 ES ES19794009T patent/ES2983950T3/es active Active
- 2019-04-26 HR HRP20240907TT patent/HRP20240907T1/hr unknown
- 2019-04-26 WO PCT/US2019/029393 patent/WO2019210200A1/en not_active Ceased
- 2019-04-26 AU AU2019260738A patent/AU2019260738B2/en active Active
- 2019-04-26 KR KR1020207033772A patent/KR102787533B1/ko active Active
- 2019-04-26 BR BR112020021949-5A patent/BR112020021949A2/pt not_active Application Discontinuation
- 2019-04-26 EP EP24179088.0A patent/EP4435000A3/en active Pending
- 2019-04-26 IL IL278304A patent/IL278304B2/en unknown
- 2019-04-26 JP JP2020560257A patent/JP7704529B2/ja active Active
- 2019-04-26 CN CN201980028704.0A patent/CN112074290B/zh active Active
- 2019-04-26 SG SG11202009734VA patent/SG11202009734VA/en unknown
- 2019-04-26 JO JOP/2020/0266A patent/JOP20200266A1/ar unknown
- 2019-04-26 CA CA3097656A patent/CA3097656A1/en active Pending
- 2019-04-26 FI FIEP19794009.1T patent/FI3784269T3/fi active
- 2019-04-26 SI SI201930780T patent/SI3784269T1/sl unknown
- 2019-04-26 CN CN202411099363.5A patent/CN118994152A/zh active Pending
- 2019-04-26 EP EP19794009.1A patent/EP3784269B1/en active Active
- 2019-04-26 MX MX2020011290A patent/MX2020011290A/es unknown
- 2019-04-29 TW TW108114935A patent/TW202014206A/zh unknown
-
2020
- 2020-10-27 SA SA520420426A patent/SA520420426B1/ar unknown
-
2024
- 2024-12-27 JP JP2024232254A patent/JP2025060958A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6932389B2 (ja) | 標的化コンジュゲートならびにその粒子及び製剤 | |
| JP5960890B2 (ja) | 担体ナノ粒子ならびに関連する組成物、方法およびシステム | |
| JP2021050212A (ja) | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム | |
| JP2023541427A (ja) | 骨格筋送達プラットフォーム及び使用方法 | |
| JP2021501754A5 (enExample) | ||
| US20160193354A1 (en) | Antisense oligonucleotides with improved pharmacokinetic properties | |
| Fuentes-Paniagua et al. | Thiol-ene synthesis of cationic carbosilane dendrons: a new family of synthons | |
| EA014097B1 (ru) | ОЛИГОНУКЛЕОТИДЫ ЗАМКНУТОЙ НУКЛЕИНОВОЙ КИСЛОТЫ (LNA) ДЛЯ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HIF-1a И ИХ ПРИМЕНЕНИЕ | |
| KR20150100706A (ko) | 입자 내에 캡슐화된 표적화된 콘쥬게이트 및 이의 제형 | |
| UA125655C2 (uk) | Терапевтичні дендримери | |
| JP2011514423A (ja) | 生分解性架橋分枝状ポリ（アルキレンイミン） | |
| CN105007905A (zh) | 靶向纳米粒子 | |
| CN116348150A (zh) | 用于递送治疗剂的脂质缀合物 | |
| AU2024291722A1 (en) | Targeted chemical drug and preparation method therefor, pharmaceutical composition, and use of targeted chemical drug | |
| JP6316209B2 (ja) | αＶβ３を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体 | |
| BR112020021949A2 (pt) | ligantes dirigidos à integrina e seus usos | |
| DK2806897T3 (en) | INTEGRIN ANAGONIST CONJUGATES FOR TARGETED RELEASE TO LFA-1 EXPRESSING CELLS | |
| US20130011448A1 (en) | System for improved delivery of gene modulating compounds | |
| JP2001515060A (ja) | 新リポポリアミン、その調製および適用 | |
| MX2014008403A (es) | Conjugados de antagonista de la integrina para su suministro dirigido a celulas que expresan vla-4. | |
| US20200046846A1 (en) | Modified oligonucleotides and therapeutic uses thereof | |
| US9447035B2 (en) | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | |
| US20090142391A1 (en) | Conjugated RNAi Therapeutics | |
| Panda et al. | Targeted leukemia therapy with solid–lipid nanoparticles: Potential and progress | |
| HK1202426B (en) | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 |